DRAP Bans 17 Substandard Auto-Disable Syringe Batches in Pakistan

Pakistan’s Crackdown on Unsafe Syringes

The Drug Regulatory Authority of Pakistan (DRAP) has declared 17 batches of auto-disable syringes substandard, sparking urgent concerns about patient safety. These syringes, produced by 11 companies, were designed to prevent reuse but failed critical safety checks.

Laboratory testing at the Central Drug Laboratory (CDL) and the Drug Testing Laboratory (DTL) in Karachi revealed that the locking mechanisms were defective. Instead of disabling after use, the syringes could be reused, creating a dangerous pathway for the spread of infectious diseases such as hepatitis and HIV.

In response, DRAP issued immediate medical product alerts and enforced a nationwide ban on the sale and use of these syringes. Provincial authorities have been tasked with conducting market surveys, seizing affected stocks, and ensuring their removal from circulation. Manufacturers, importers, and distributors have also been ordered to recall the faulty batches without delay.

The banned syringes include three batches imported from China, while others were produced locally in Punjab and Khyber Pakhtunkhwa. DRAP stressed that syringe reuse undermines patient safety and could trigger widespread health crises if not addressed swiftly.

This decisive crackdown underscores Pakistan’s commitment to enforcing strict medical standards and protecting citizens from unsafe healthcare products. By removing these substandard syringes from the market, DRAP aims to safeguard public health and restore trust in medical supplies.